We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th.
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in in-vivo CRISPR gene editing. The company is among the first to demonstrate systemic CRISPR efficacy in humans, targeting diseases like ATTR amyloidosis and hereditary angioedema, with one-time treatments that could replace chronic therapies.
If successful, this positions Intellia at the forefront of a new drug category—genomic surgery—validated by partnerships with major pharma players such as Regeneron, Novartis, and Vertex. While regulatory standards are still evolving and long-term safety remains unproven, the platform’s potential for expansion across multiple monogenic diseases offers enormous optionality.
Intellia’s market opportunity is significant, with ATTR and HAE representing multi-billion-dollar markets and pricing for one-time therapies expected between $500,000 and $2 million per patient. Gross margins for such therapies could exceed 80%, and the platform could eventually extend into oncology and CNS disorders.
The company has a strong balance sheet, typically maintaining over $700 million in cash, supported by partner funding, and a low-debt structure, providing a runway of 2–3 years without additional financing. Institutional backing is robust, with major biotech funds and Regeneron holding significant stakes, although volatility in risk-off markets could pressure the stock.
The path to value creation is clear, with upcoming catalysts including Phase 2/3 data for NTLA-2001 (ATTR), Phase 2 data for NTLA-2002 (HAE), FDA regulatory feedback, and potential commercial filings. While clinical setbacks, long-term safety issues, or competitive advances could severely impact the stock, the bull case is compelling: multiple approved drugs could validate the platform and drive a $20–30 billion market capitalization. Intellia offers a high-risk, high-reward proposition for investors willing to back a true biotech innovator poised to redefine treatment paradigms.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial potential, early patient uptake, outcomes-based reimbursement, and a strong pipeline including in vivo liver editing. CRSP’s stock price has appreciated by approximately 30.63% since our coverage. Danny Green shares a similar view but emphasizes Intellia Therapeutics, Inc.’s (NTLA) in-vivo CRISPR work and optionality across monogenic diseases.
Leave a Reply